Addyi Regulatory Status: US, EU, Canada, UK

How Flibanserin Works: Mechanism of Action

Flibanserin acts on central nervous system neurotransmitter pathways involved in sexual desire. It is a postsynaptic serotonin 5-HT1A receptor agonist and a 5-HT2A receptor antagonist, a dual action that shifts the balance between inhibitory serotonergic signaling and excitatory dopaminergic and noradrenergic signaling in the prefrontal cortex 1.

Serotonin-Dopamine Rebalancing

Preclinical microdialysis studies in rats showed that flibanserin increases dopamine and norepinephrine release in the medial prefrontal cortex while transiently reducing serotonin levels 2. This neurochemical shift is thought to reduce the serotonergic "brake" on sexual motivation. The drug does not affect peripheral vascular smooth muscle or hormonal axes, distinguishing it from phosphodiesterase-5 inhibitors and hormonal therapies 1.

Why Bedtime Dosing Matters

Flibanserin causes somnolence, dizziness, and hypotension in a dose-dependent manner. The FDA label specifies bedtime administration to minimize these effects during waking hours 3. Peak plasma concentration occurs approximately 45 minutes after oral dosing, with a terminal half-life of roughly 11 hours 4. Patients who forget a bedtime dose should skip it rather than take it the following morning.

US Regulatory History: Two Rejections Before Approval

The FDA path for flibanserin was long and contested. Sprout Pharmaceuticals submitted three separate applications before receiving approval, making Addyi one of the most debated drug approvals in recent FDA history.

The 2010 and 2013 Complete Response Letters

The FDA first rejected flibanserin in 2010, citing insufficient efficacy and safety concerns including sedation, dizziness, and syncope 5. A second rejection followed in 2013 for similar reasons. Between these rejections, an FDA advisory committee voted 11-to-0 against approval in June 2010, finding the drug's benefit on sexual desire did not outweigh its risks 6.

The 2015 Advisory Committee and Approval

A reconvened advisory committee in June 2015 voted 18-to-6 in favor of approval, with the stipulation that a REMS program be required 5. The FDA approved flibanserin on August 18, 2015, restricted to premenopausal women with acquired, generalized HSDD 3. The approval was based on pooled data from three phase III trials (VIOLET, DAISY, and BEGONIA) enrolling approximately 2,400 women total.

Key Trial Outcomes

In the BEGONIA trial (N=1,087), flibanserin 100 mg at bedtime produced a statistically significant increase in satisfying sexual events (SSEs) compared with placebo: a mean increase of 0.8 additional SSEs per month over a 24-week treatment period 7. The co-primary endpoint of sexual desire, measured by the Female Sexual Function Index (FSFI) desire domain, improved by 0.3 points on a 1.2-to-6.0 scale versus placebo 7. Critics noted this magnitude of improvement was modest. Pooled analysis across all three trials showed similar effect sizes: approximately 0.5 to 1.0 additional SSEs per month 8.

The REMS Program: Prescribing and Dispensing Restrictions

The Addyi REMS program is among the more restrictive frameworks the FDA has imposed on an outpatient oral medication. It requires certification of both prescribers and pharmacies before the drug can be ordered or dispensed 9.

Prescriber Certification Requirements

Prescribers must complete an online training module and enroll in the REMS program. They are required to counsel patients on three specific risks: the interaction between flibanserin and alcohol that can cause severe hypotension and syncope, the interaction with moderate or strong CYP3A4 inhibitors, and the additive risk with other CNS depressants 9. A dedicated alcohol interaction study in 25 subjects showed that concurrent consumption led to hypotension requiring intervention in 4 of 25 participants (16%) 10.

REMS Modifications Over Time

In 2019, the FDA modified the REMS to remove the absolute alcohol contraindication, replacing it with a recommendation that patients avoid alcohol during treatment. The agency cited real-world pharmacovigilance data from over 30,000 women prescribed Addyi showing lower rates of hypotension and syncope than the controlled alcohol interaction trial had predicted 11. This change simplified prescribing but did not eliminate the REMS requirement itself.

European Medicines Agency: Application Withdrawn

Flibanserin never received marketing authorization in the European Union. Boehringer Ingelheim, the original developer, withdrew its marketing authorization application from the EMA in October 2010, before the Committee for Medicinal Products for Human Use (CHMP) issued a final opinion 12.

Reasons for the EU Withdrawal

The CHMP's preliminary assessment concluded that flibanserin's efficacy over placebo was not clinically meaningful and that the safety profile, particularly CNS depression and drug interactions, was concerning 12. The committee raised questions about the validity of the primary endpoint (SSEs) as a measure of desire, arguing that satisfying sexual events may reflect arousal and relationship factors rather than desire itself 13. No subsequent application has been filed with the EMA.

Implications for EU Patients

Without EMA approval, flibanserin cannot be legally prescribed or dispensed in any EU member state. Off-label importation pathways exist in some countries for individual patients, but these are rarely used for flibanserin given the availability of alternative approaches such as psychotherapy, testosterone (off-label), and bremelanotide in jurisdictions where it is available 14.

Canada: No Approval Granted

Health Canada has not approved flibanserin. No Notice of Compliance has been issued for the drug, and it does not appear in the Drug Product Database as of 2026 15.

Regulatory Pathway Considerations

The Canadian regulatory framework for HSDD treatments has been limited. Bremelanotide (Vyleesi), approved by the FDA in 2019, also lacks Health Canada approval. Canadian clinicians treating HSDD in premenopausal women typically rely on off-label testosterone therapy, informed by the International Society for the Study of Women's Sexual Health (ISSWSH) guidelines, or cognitive behavioral interventions 16.

Access Through Special Programs

Canada's Special Access Programme (SAP) permits physicians to request drugs not marketed in Canada for patients with serious or life-threatening conditions when conventional therapies have failed. HSDD, while distressing, is not typically classified as life-threatening, making SAP requests for flibanserin uncommon in practice.

United Kingdom: Not Licensed

Flibanserin holds no marketing authorization from the UK's Medicines and Healthcare products Regulatory Agency (MHRA). Prior to Brexit, the UK fell under EMA jurisdiction, and the 2010 withdrawal applied equally. Since the UK established its own regulatory pathway in January 2021, no sponsor has submitted a new application for flibanserin to the MHRA 17.

UK Clinical Practice for HSDD

British clinicians managing HSDD follow guidance from the British Society for Sexual Medicine and NICE. Current practice favors psychosexual therapy as a first-line intervention 17. Off-label transdermal testosterone at 300 mcg/day has gained traction in the UK following the 2019 global consensus position statement endorsed by ISSWSH, the Endocrine Society, and multiple other organizations 16.

Safety Profile Across Regulatory Reviews

Every regulatory body that reviewed flibanserin identified the same core safety signals. The consistency of these findings across independent reviews is notable.

CNS Depression and Syncope

Across pooled phase III data, somnolence occurred in 11.4% of flibanserin-treated patients versus 3.9% on placebo. Dizziness affected 11.4% versus 2.2%, and fatigue 9.2% versus 5.3% 3. Syncope occurred in 0.4% of flibanserin-treated women in controlled trials. The risk increased substantially with concomitant alcohol: a dedicated study found that 4 of 23 women (17%) experienced hypotension or syncope requiring positioning or IV fluids when flibanserin was combined with alcohol 10.

Drug Interaction Profile

Flibanserin is primarily metabolized by CYP3A4, with secondary contributions from CYP2C19 4. Concomitant use with moderate or strong CYP3A4 inhibitors (fluconazole, ketoconazole, certain HIV protease inhibitors) increases flibanserin AUC by 4.5-fold to 7-fold, creating substantial hypotension risk 3. The FDA label contraindicates use with these agents. This interaction profile contributed to every regulatory body's safety concerns and remains the primary reason for the REMS in the US.

Efficacy Debate: Clinically Meaningful or Not?

The central controversy in flibanserin's regulatory history is whether its statistical efficacy translates to clinical meaningfulness. The answer depends on which metric you prioritize.

Desire Versus Events

The FSFI desire domain improvement of 0.3 points over placebo in BEGONIA 7 fell below the 0.4-point threshold that some researchers considered the minimal clinically important difference. The SSE endpoint showed approximately 0.5 to 1.0 additional events per month across trials 8. Patient Global Impression of Improvement (PGI-I) data were more encouraging: in the BEGONIA trial, 49.8% of flibanserin-treated women rated themselves as "much improved" or "very much improved" versus 35.9% on placebo 7.

Comparison With Other Sexual Dysfunction Drugs

Sildenafil's approval for erectile dysfunction was supported by 60% to 80% response rates versus 20% to 25% for placebo. Flibanserin's effect sizes are considerably smaller. A 2016 systematic review and meta-analysis in JAMA Internal Medicine (N=5,914 across eight trials) found flibanserin produced 0.49 additional SSEs per month versus placebo, with a number needed to treat (NNT) of 8 for any response on the PGI-I 18. The same meta-analysis estimated a number needed to harm (NNH) of 7 for dizziness and 12 for somnolence.

Post-Marketing Surveillance and Uptake

Despite its historic significance as the first FDA-approved drug for female sexual desire, commercial uptake of Addyi has been limited.

Prescription Volume

In the first year after approval, approximately 6,000 prescriptions were filled nationwide, far below initial projections 19. The REMS requirement, limited insurance coverage, and a cash price exceeding $800 per month all contributed to low adoption. Sprout Pharmaceuticals (acquired by Valeant, now Bausch Health, shortly after approval) attempted to expand access through a direct-to-patient model, but uptake remained modest.

Ongoing Pharmacovigilance

The FDA continues to monitor post-marketing safety reports through FAERS. Updated labeling in 2019 reflected the REMS modification regarding alcohol 11. No new safety signals have emerged beyond those identified in preapproval trials. Hepatotoxicity, initially a theoretical concern given CYP3A4 metabolism, has not materialized as a clinical problem in post-marketing data.

The Broader Field of HSDD Pharmacotherapy

Flibanserin's regulatory trajectory shaped how subsequent HSDD drugs were developed and reviewed.

Bremelanotide as an Alternative

The FDA approved bremelanotide (Vyleesi) in June 2019 for premenopausal HSDD, providing an on-demand subcutaneous injection alternative. The RECONNECT trials (N=1,247) showed statistically significant improvements in FSFI desire scores and reductions in distress 14. Bremelanotide works through melanocortin-4 receptor activation rather than serotonin modulation, and it does not carry the same alcohol interaction risk. It does cause nausea in approximately 40% of patients 14.

Off-Label Testosterone

The 2019 global consensus position statement recommended transdermal testosterone for postmenopausal women with HSDD, based on data from trials totaling over 3,000 women showing a mean increase of 0.85 SSEs per month versus placebo 16. No testosterone product is FDA-approved for women, though off-label use is widespread. For premenopausal women, evidence supporting testosterone for HSDD is less strong.

Clinicians prescribing flibanserin should confirm CYP3A4 inhibitor status, counsel on alcohol avoidance, and reassess efficacy at 8 weeks, discontinuing the drug if no improvement in desire or SSEs is observed 3.